Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Carcinoma, Intraductal, Noninfiltrating 2Mammographically Dense Breast 1

Interventions

Tamoxifen 9Letrozole 5Anastrozole 5Radiotherapy 3Radiation 3Neoadjuvant Therapy 3afimoxifene 2Trastuzumab 2Surgical Procedures, Operative 2Simvastatin 2Sentinel Lymph Node Biopsy 2Radiation Dose Hypofractionation 2Mastectomy, Segmental 2Lapatinib 2Gene Expression Profiling 2trastuzumab biosimilar HLX02 1telapristone acetate 1sargramostim 1polyphenon E 1pasireotide 1palbociclib 1oxybutynin 1liposomal doxorubicin 1exemestane 1Zoledronic Acid 1UAB 30 1Tea 1Sugars 1Specimen Handling 1Radiotherapy, Intensity-Modulated 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Carcinoma, Intraductal, Noninfiltrating × afimoxifene × Clear all
NCT02993159 2024-12-18

Testing an Active Form of Tamoxifen (4-hydroxytamoxifen) Delivered Through Breast Skin to Control Ductal Carcinoma in Situ (DCIS) of the Breast

Northwestern University

Phase 2 Completed
100 enrolled 15 charts
Breast

Carcinoma, Intraductal, Noninfiltrating

NCT00952731 2015-07-21

4-Hydroxytamoxifen or Tamoxifen Citrate in Treating Women With Newly Diagnosed Ductal Breast Carcinoma in Situ

Northwestern University

Phase 2 Completed
27 enrolled 12 charts
Breast

Carcinoma, Intraductal, Noninfiltrating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡